Efficacy
Aimovig ® has demonstrated benefit across the migraine spectrumReferences
Goadsby PJ, Reuter U, Hallstrom Y, et al. A controlled trial of erenumab for episodic migraine. N Engl J Med,...Twitter Linkedin Facebook Pinterest Google plusIndication
Aimovig ® is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month.
Although the reimbursement criteria in Belgium are more restrictive, Aimovig® is indicated for prophylaxis of...
Twitter Linkedin Facebook Pinterest Google plusReimbursement
Aimovig ® reimbursement criteria in Belgium and LuxembourgIn Luxembourg , Aimovig ® (70mg and 140mg) is reimbursed at 80% in line with the EU label (for...
Twitter Linkedin Facebook Pinterest Google plusSafety Profile
SAFETY AND TOLERABILITY PROFILE _
ü No additional monitoring needed 1 . ü Based on clinical trial experience in > 3.000 patients, the overall incidence of adverse events with Aimovig ® was comparable to placebo ...Twitter Linkedin Facebook Pinterest Google plusAimovig® (Erenumab)
Aimovig ® is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month.Twitter Linkedin Facebook Pinterest Google plus
×